The global hemostasis/coagulation analyzers market was valued at USD 3.65 billion in 2017 and is expected to grow at a CAGR of 9.9% over the period 2018 to 2026 to reach USD 9.55 billion by 2026, driven mainly by the growing incidence of blood disorders.

A clinical assay from Zeesan Biotech to detect and identify 14 high-risk genotypes of human papillomavirus has been approved by the China State Food and Drug Administration, company announced recently.

The global medical gas analyzers market was valued at USD 235 million in 2017 and is expected to grow at a CAGR of 4.1% from 2018 to 2025 to reach USD 325 million by 2025

BioMérieux reported today that its third quarter revenues grew 7 percent year over year driven in part by strong growth in its molecular biology clinical applications.

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions.

IDEX Health & Science, LLC (IH&S) today announced the acquisition of Lima, NY based Finger Lakes Instrumentation, LLC (FLI).

Illumina reported after the close of the market on Monday that its second quarter 2018 revenues rose by 25 percent year over year.

PerkinElmer reported after the close of the market on Wednesday that its second quarter revenues grew 29 percent year over year as the company beat analyst estimates on the top and bottom lines.

NEW YORK (GenomeWeb) — Bruker said on Thursday that it has acquired Berlin-based JPK Instruments for an undisclosed amount.

Illumina said after the close of the market recently that it intends to offer approximately $650 million of convertible senior notes due 2023.

Bio-Rad Laboratories reported after the close of the market recently that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses.

Finnish consumer genetic testing firm Negen has turned to BC Platforms for analysis of raw genomic data for clinical reporting purposes, the companies announced recently.

Recently, leading molecular diagnostic data analysis startup Tempus announced the completion of E round of financing, with a total financing of 110 million dollars.

The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).

NEW YORK (GenomeWeb) – Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays.